Baidu
map

BMJ:继发于西地那非治疗后的视网膜静脉阻塞 -案例报道

2017-03-27 xing.T MedSci原创

没有发现特殊的原因,但进一步的问诊显示该患者经常服用西地那非治疗勃起功能障碍。西地那非已知的副作用是引起视网膜血管阻塞。

患者为一名73岁男性,因其右眼黄斑中有棉絮斑(图1)而就诊。十来天后,该患者发展为视网膜浅层出血,并且被诊断出为右侧视网膜分支静脉阻塞。


图1

该患者视力为6/15,没有糖尿病高血压病史,凝血功能检查结果正常。没有发现特殊的原因,但进一步的问诊显示该患者经常服用西地那非治疗勃起功能障碍。西地那非已知的副作用是引起视网膜血管阻塞。

这个病例中,当医生面对无明显原因的血管性眼睛病变时,了解患者全面的用药史变得尤为重要。

原始出处:

Hussein Almuhtaseb. et al. Branch retinal vein occlusion secondary to sildenafil. BMJ2017;356:j753 doi: 10.1136/bmj.j753  

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697430, encodeId=56dd169e4308b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 02 13:06:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724435, encodeId=12aa1e2443594, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Dec 30 13:06:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848276, encodeId=71af18482e627, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Feb 03 18:06:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696706, encodeId=97d61696e06ea, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Jul 28 08:06:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269854, encodeId=25a01269854c6, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581618, encodeId=080715816189a, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca5e16842121, createdName=passed water, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-06-02 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697430, encodeId=56dd169e4308b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 02 13:06:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724435, encodeId=12aa1e2443594, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Dec 30 13:06:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848276, encodeId=71af18482e627, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Feb 03 18:06:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696706, encodeId=97d61696e06ea, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Jul 28 08:06:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269854, encodeId=25a01269854c6, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581618, encodeId=080715816189a, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca5e16842121, createdName=passed water, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-12-30 feifers
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697430, encodeId=56dd169e4308b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 02 13:06:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724435, encodeId=12aa1e2443594, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Dec 30 13:06:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848276, encodeId=71af18482e627, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Feb 03 18:06:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696706, encodeId=97d61696e06ea, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Jul 28 08:06:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269854, encodeId=25a01269854c6, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581618, encodeId=080715816189a, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca5e16842121, createdName=passed water, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2018-02-03 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697430, encodeId=56dd169e4308b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 02 13:06:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724435, encodeId=12aa1e2443594, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Dec 30 13:06:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848276, encodeId=71af18482e627, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Feb 03 18:06:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696706, encodeId=97d61696e06ea, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Jul 28 08:06:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269854, encodeId=25a01269854c6, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581618, encodeId=080715816189a, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca5e16842121, createdName=passed water, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-07-28 tomyang96
  5. [GetPortalCommentsPageByObjectIdResponse(id=1697430, encodeId=56dd169e4308b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 02 13:06:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724435, encodeId=12aa1e2443594, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Dec 30 13:06:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848276, encodeId=71af18482e627, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Feb 03 18:06:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696706, encodeId=97d61696e06ea, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Jul 28 08:06:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269854, encodeId=25a01269854c6, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581618, encodeId=080715816189a, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca5e16842121, createdName=passed water, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-29 zutt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1697430, encodeId=56dd169e4308b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 02 13:06:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724435, encodeId=12aa1e2443594, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Dec 30 13:06:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848276, encodeId=71af18482e627, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Feb 03 18:06:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696706, encodeId=97d61696e06ea, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Jul 28 08:06:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269854, encodeId=25a01269854c6, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581618, encodeId=080715816189a, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca5e16842121, createdName=passed water, createdTime=Wed Mar 29 07:06:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]

相关资讯

Circulation:西地那非治疗心梗后舒张功能不全效果不佳

西地那非组(正方形)和安慰剂组(圆)的基线(空心)和随访(实心)时的左室舒张末容积指数(LVEDVI; x 轴)和肺毛细血管楔压(PCWP; y 轴) 心肌梗死后的舒张功能不全比较常见,其特点是为保证运动时的每搏输出量导致心室过度充盈。丹麦的Andersen MJ医生等提出假设西地那非可以减少心梗后舒张功能不全患者的运动时的左室充盈压并对此进行研究。文章发表在2013年3月19日《循环》杂志

Circulation:西地那非不能降低心肌梗死后心脏舒张功能不全患者的心室充盈压

舒张性心功能不全是心肌梗死后的常见并发症,其主要特点是心脏为了维持运动时必要的心搏量而不适当地增加心室充盈压,因此,心室充盈压的一场增高时心脏舒张功能不全的主要指标。为了验证西地那非是否可以降低心肌梗死后并发舒张性心功能不全患者的心室充盈压,丹麦哥本哈根大学医学院心脏中心的Mads J. Andersen教授及其同事开展了一项研究,其研究结果发表在2013年3月19日的《循环》(Circulati

JCEM:治疗勃起功能障碍的药物或可用于预防糖尿病的发生

JCEM:治疗勃起功能障碍的药物或可用于预防糖尿病的发生据发表于《临床内分泌代谢杂志》的一项新的研究表明,西地那非,即我们所熟知的伟哥或其他治疗勃起功能障碍药物的有效成分,可提高易患糖尿病人群的胰岛素敏感性。西地那非可抑制磷酸二酯酶5(PDE5),导致平滑肌松弛,血管扩张,血流量增加,它常用于治疗男性勃起功能障碍,还可用于治疗肺动脉高压。动物研究表明,西地那非可改善机体的胰岛素敏感性,提高其从血液

Obstet Gynecol:枸橼酸西地那非治疗羊水过少

由此可见,枸橼酸西地那非增加了妊娠合并羊水过少患者的羊水体积。

药监局警告:凡是”改善男性性功能“的保健食品都违法

。国家食品药品监督管理总局(CFDA)5月13日为此发文称,食品或保健食品等中添加西地那非属违法行为,凡已批准注册的保健食品宣传“改善男性性功能”均属虚假宣传。

J Clin Endocrinol Metab:PDE5抑制剂可改善糖尿病前期患者胰岛素敏感性

一项新的研究发现勃起功能障碍药物西地那非(伟哥)改善糖尿病前期患者的胰岛素敏感性和内皮功能标志物状态。研究结果11月18日在线发表在Journal of Clinical Endocrinology and Metabolism。

Baidu
map
Baidu
map
Baidu
map